Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01805492 · ClinicalTrials.gov registry record · NA

Global Profiling of Gene and Protein Expression Associated With Coronary Heart Disease Reversal

A NA study of Cardiovascular Diseases and Heart Diseases, sponsored by Windber Research Institute.

Completed
Registry status
NA
Development phase
422
Enrollment target
1
Study location

NCT01805492: Completed NA study of Cardiovascular Diseases and Heart Diseases, sponsored by Windber Research Institute.

NCT01805492 is a NA study of Cardiovascular Diseases and Heart Diseases that has completed, run by Windber Research Institute. The registered enrollment target is 422 participants, below the 26,973-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01805492, a NA study of Cardiovascular Diseases and Heart Diseases, has completed, sponsored by Windber Research Institute.

COMPLETED
Registry status
NA
Development phase
422 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to characterize changes in gene and protein expression in peripheral blood in patients with, or at risk for, heart disease during an intensive lifestyle modification program.

Primary Outcome

Change in BMI from baseline to 12 weeks and from baseline to 52 weeks

Interventions

  • BEHAVIORAL Dr. Dean Ornish Program for Reversing Heart Disease

Study Locations (1)

Pennsylvania

  • Windber Medical Center - Windber

Trial Details

FieldValue
Enrollment Target 422 participants
Start Date 2000-01
Est. Completion 2009-02
Phase NA
Windber Research Institute

2 total trials

What the finished NCT01805492 record still lists

NCT01805492 is an interventional study that assigns participants to a tested intervention. The registered 422 participants enrollment target is mid-sized for trials with a published cap, below the 26,973-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (98% lower).

The record links to 2 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 1 intervention - of which Dr. Dean Ornish Program for Reversing Heart Disease is the first listed.

NCT01805492 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT01805492 about?

NCT01805492 is a clinical study titled "Global Profiling of Gene and Protein Expression Associated With Coronary Heart Disease Reversal". The purpose of this study is to characterize changes in gene and protein expression in peripheral blood in patients with, or at risk for, heart disease during an intensive lifestyle modification program.

What is the current status of trial NCT01805492?

This trial is currently completed. It is a NA study. The enrollment target is 422 participants. The study started on 2000-01. Estimated completion is 2009-02.

What conditions does trial NCT01805492 study?

This clinical trial studies the following conditions: Cardiovascular Diseases, Heart Diseases.

What interventions are being tested in trial NCT01805492?

The interventions under investigation include: Dr. Dean Ornish Program for Reversing Heart Disease (BEHAVIORAL).

Who is sponsoring clinical trial NCT01805492?

This trial is sponsored by Windber Research Institute, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01805492 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cardiovascular Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01805492's enrollment target sits among peer trials

422 103rd of 300 higher than 198 of 300 other Cardiovascular Diseases trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cardiovascular Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04763356 · 422 participants · NA

    Remote Monitoring and Management of Chemotherapy Induced Peripheral Neuropathy

  • NCT06837246 · 422 participants · NA

    A Clinical Trial to Assess Cognitive Effects of Cognitive Nutritional Supplement in General Population

  • NCT07298967 · 422 participants · NA

    ORCHARDS-AIR Study

  • NCT06935591 · 423 participants · NA

    Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01805492, the US trial registry maintained by the National Library of Medicine. NCT01805492 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.